Cargando…

Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment

This study aimed to assess the pharmacokinetics of cyclosporine A (CsA) in Asian children with renal impairment (RI) by developing a physiologically-based pharmacokinetic (PBPK) model with Simcyp Simulator. The PBPK model of Asian children with RI was developed by modifying the physiological paramet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Sumin, Yi, Sojeong, Rhee, Su-jin, Lee, Hyun A, Kim, Yun, Yu, Kyung-Sang, Chung, Jae-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989237/ https://www.ncbi.nlm.nih.gov/pubmed/32055591 http://dx.doi.org/10.12793/tcp.2019.27.3.107

Ejemplares similares

Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients
por: Baek, Hyunjeong, et al.
Publicado: (2014)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Pharmacokinetics of cyclosporin - a microemulsion in children with idiopathic nephrotic syndrome
por: dos Santos Henriques, Luciana, et al.
Publicado: (2012)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients
por: Cui, Cheng, et al.
Publicado: (2021)

Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics
por: Lee, Myongjae, et al.
Publicado: (2022)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Effects of Nigella sativa and Lepidium sativum on Cyclosporine Pharmacokinetics
por: Al-Jenoobi, F. I., et al.
Publicado: (2013)

Effects of intestinal microbiota on pharmacokinetics of cyclosporine a in rats
por: Zhou, Jinping, et al.
Publicado: (2022)

The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for Cats(®)) in Cats
por: Kong, Jingyuan, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
por: Ye, Lingling, et al.
Publicado: (2022)

Pharmacokinetics of Gepotidacin in Renal Impairment
por: Hossain, Mohammad, et al.
Publicado: (2020)

High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.
por: Bisogno, G., et al.
Publicado: (1998)

Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation
por: Li, Tai-feng, et al.
Publicado: (2019)

Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes
por: Yang, Yiting, et al.
Publicado: (2020)

Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A
por: Bertocchio, Jean-Philippe, et al.
Publicado: (2016)

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
por: Atiq, Ferdows, et al.
Publicado: (2016)

Pharmacokinetics and bioequivalence of two cyclosporine oral solution formulations in cats
por: Yang, Yuxin, et al.
Publicado: (2022)

Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
por: Mansell, Holly, et al.
Publicado: (2022)

Low cyclosporine concentrations in children and time to acute graft versus host disease
por: Chung, Eun Kyung, et al.
Publicado: (2020)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Applying machine learning to the pharmacokinetic modeling of cyclosporine in adult renal transplant recipients: a multi-method comparison
por: Mao, Junjun, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
por: Heimbach, Tycho, et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
por: Shen, Chaozhuang, et al.
Publicado: (2023)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects
por: Kim, Yun, et al.
Publicado: (2019)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Could Salivary Cyclosporine Dosage Replace the Whole Blood Cyclosporine Measurements in Renal Transplant Patients?
por: Aboujaoude, Samia, et al.
Publicado: (2017)

Influence of Overt Diabetes Mellitus on Cyclosporine Pharmacokinetics in a Canine Model
por: Alkharfy, Khalid M.
Publicado: (2009)

Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia
por: Gao, Xuan, et al.
Publicado: (2022)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Urinary Concentration Defect and Renal Glycosuria in Cyclosporine-treated Rats
por: Lee, Jun Han, et al.
Publicado: (2020)

Bioequivalence study of cyclosporine in renal transplant recipients
por: Gautam, Gagan
Publicado: (2007)

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
por: Shin, Dongseong, et al.
Publicado: (2017)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
por: Lin, Shujun, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans
por: Kim, Min-Soo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5gc6lj4ebkdttorqfgqh9oki8f